← ANALYST RATINGS · TIPRANKS
Revvity (RVTY): analyst forecast and price target
Analyst consensus
Moderate Buy4 Buy10 Hold0 Sell
Ratings of 14 analysts in the last 3 months12-month forecast
Based on 14 price targets given in the last 3 months, the average target is $142, the highest $175, the lowest $110. The average is −7.1% from the last price of $153.
Analyst ratings 22
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Casey Woodring★★★★★★★★★★#2489 · hits 62% · avg +8.2% | J.P. Morgan | $110 → $155+40.9% | Hold | +1.5% | Reiterated | 16.10.26on TipRanks Oct 17 08:15 | −0.2% | ↗ |
| Daniel Brennan★★★★★★★★★★#271 · hits 58% · avg +21.8% | TD Cowen | $130 → $175+34.6% | Buy | +14.6% | Reiterated | 13.10.26on TipRanks 08:41 | −0.3%next day −0.8% | ↗ |
| Eve Burstein★★★★★★★★★★#1300 · hits 72% · avg +25.0% | Bernstein | $120 | Hold | −21.4% | Reiterated | 12.10.26on TipRanks 06:30 | +1.0%next day −0.3% | ↗ |
| Michael Ryskin★★★★★★★★★★#1994 · hits 58% · avg +5.1% | Bank of America Securities | $125 → $165+32.0% | Hold | +8.1% | Reiterated | 09.10.26on TipRanks 08:10 | +0.7%next day +1.0% · 5 days +1.0% | ↗ |
| Luke Sergott★★★★★★★★★★#1255 · hits 49% · avg +9.8% | Barclays | $115 → $160+39.1% | Hold | +4.8% | Reiterated | 07.10.26on TipRanks 03:55 | +0.4%next day −0.5% · 5 days 0.0% | ↗ |
| Matt Larew★★★★★★★★★★#816 · hits 63% · avg +19.3% | William Blair | — | Buy | — | Initiated | 05.10.26on TipRanks 16:30 | −3.1%next day +0.4% · 5 days +1.3% | ↗ |
| Evie Koslosky★★★★★★★★★★#9740 · hits 58% · avg −3.1% | Goldman Sachs | $100 → $140+40.0% | Hold | −8.3% | Reiterated | 20.09.26on TipRanks Sep 21 08:15 | −1.5%next day −0.2% · 5 days +6.2% | ↗ |
| Unknown Analyst | CFRA | — | Hold | — | Downgrade | 18.09.26on TipRanks Sep 21 08:15 | −2.4%next day −1.5% · 5 days +4.1% | ↗ |
| AI xAi Medical - Diagnostics and ResearchxAI Grok-3 | TipRanks - xAI | $140 → $156+11.4% | Buy | +2.2% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI DeepSeek Medical - Diagnostics and ResearchDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $137 → $156+13.9% | Buy | +2.2% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI OpenAI Medical - Diagnostics and ResearchOpenAI 5.2 | TipRanks - OpenAI | $137 → $154+12.4% | Hold | +0.9% | Downgrade | 16.09.26on TipRanks 13:05 | — | |
| AI Anthropic Medical - Diagnostics and ResearchAnthropic Opus-4.5 | TipRanks - Anthropic | $125 → $146+16.8% | Hold | −4.4% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI Google Medical - Diagnostics and ResearchGemini 3-pro | TipRanks - Google | $140 → $157+12.1% | Buy | +2.9% | Reiterated | 16.09.26on TipRanks 13:05 | — | |
| AI PerPlexity Medical - Diagnostics and ResearchPerPlexity SonarPro | TipRanks - PerPlexity | $137 → $154+12.4% | Hold | +0.9% | Downgrade | 16.09.26on TipRanks 13:05 | — | |
| Unknown Analyst | UBS | $120 → $140+16.7% | Hold | −8.3% | Initiated | 08.09.26on TipRanks Sep 9 06:50 | −1.9%next day −2.1% · 5 days +11.4% | ↗ |
| Paul Knight★★★★★★★★★★#4215 · hits 45% · avg +3.5% | KeyBanc | $125 → $165+32.0% | Buy | +8.1% | Reiterated | 04.09.26on TipRanks 07:05 | +0.1%next day −1.9% · 5 days −0.1% | ↗ |
| Dan Leonard★★★★★★★★★★#656 · hits 62% · avg +14.1% | RBC Capital | $135 | Hold | −11.6% | Initiated | 01.09.26on TipRanks 05:20 | −0.9%next day +3.0% · 5 days −2.2% | ↗ |
| Vijay Kumar★★★★★★★★★★#2375 · hits 54% · avg +4.8% | Evercore ISI | $125 → $126+0.8% | Buy | −17.5% | Reiterated | 05.08.26on TipRanks 08:20 | +3.5%next day −0.5% · 5 days +2.1% | ↗ |
| Unknown Analyst | Wells Fargo | $110 | Hold | −27.9% | Reiterated | 05.08.26on TipRanks 08:05 | +3.5%next day −0.5% · 5 days +2.1% | ↗ |
| Daniel Arias★★★★★★★★★★#1848 · hits 50% · avg +8.0% | Stifel Nicolaus | $100 → $110+10.0% | Hold | −27.9% | Assigned | 05.08.26on TipRanks 07:15 | +3.5%next day −0.5% · 5 days +2.1% | ↗ |
| Puneet Souda★★★★★★★★★★#2942 · hits 45% · avg +4.1% | Leerink Partners | — | Buy | — | Reiterated | 17.07.26on TipRanks Jul 19 10:25 | −0.3%next day −3.2% · 5 days +0.9% | ↗ |
| Michael Polark★★★★★★★★★★#2909 · hits 51% · avg +6.5% | Wolfe Research | — | Hold | — | Initiated | 01.06.26on TipRanks 16:45 | −0.3%next day +1.4% · 5 days +6.7% | ↗ |
| Unknown Analyst | Guggenheim | — | Hold | — | Reiterated | 11.05.26on TipRanks May 14 06:35 | −2.3%next day +0.5% · 5 days −3.4% | ↗ |
| Catherine Ramsey Schulte★★★★★★★★★★#864 · hits 53% · avg +11.2% | Robert W. Baird | $129 → $117−9.3% | Buy | −23.3% | Reiterated | 04.05.26on TipRanks 06:35 | +0.2%next day +5.9% · 5 days +11.4% | ↗ |
| Jack Meehan★★★★★★★★★★#787 · hits 68% · avg +14.4% | Nephron | $90.00 | Hold | −41.0% | Upgrade | 26.03.26on TipRanks 07:20 | +1.0%next day −2.0% · 5 days +0.4% | ↗ |
| Tycho Peterson★★★★★★★★★★#1097 · hits 57% · avg +9.8% | Jefferies | $100 → $105+5.0% | Hold | −31.2% | Reiterated | 02.02.26on TipRanks 14:35 | −2.1%next day −4.7% · 5 days −3.8% | ↗ |
| Unknown Analyst | Citi | — | Buy | — | Reiterated | 05.01.26on TipRanks 08:05 | +3.3%next day +2.3% · 5 days +0.7% | ↗ |
| Andrew Cooper★★★★★★★★★★#11107 · hits 40% · avg −3.0% | Raymond James | $115 | Buy | −24.7% | Reiterated | 28.10.25on TipRanks 10:20 | −1.0%next day −1.2% · 5 days −3.2% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Revvity
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $127 at a price of $153 (−16.7%); now: $142 at $153 (−7.1%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 3 | 4 | 6 | 6 | 6 | 5 |
| Hold | 11 | 11 | 10 | 8 | 12 | 15 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
Earnings and sales forecast
Next report: 03.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.30 (from $1.28 to $1.33). Last quarter: $1.41.
Sales
Next quarter’s sales estimate — $695M (from $691M to $703M). Last quarter: $730M.
Best top-analyst consensus in the sector · Healthcare
About Revvity
- CEO: Prahlad R. Singh
- Employees: 11,000
- 77 4th Avenue, Waltham, MA, 02451, US
- www.revvity.com
Revvity, Inc., founded in 1937 and based in Waltham, Massachusetts, is a global enterprise that develops and delivers a wide array of products, services, and solutions. The company, which changed its name from PerkinElmer, Inc. in April 2023, caters to the diagnostics, life sciences, and applied services sectors worldwide. Its Discovery & Analytical Solutions division provides advanced instrumentation, reagents, informatics, software, subscriptions, and sophisticated detection and imaging technologies. These resources are designed to enable scientists to achieve significant breakthroughs in life sciences research. This segment also offers contract research and specialized laboratory services. Furthermore, it supplies analytical tools and services for assessing environmental health, including air, water, and soil, and delivers solutions to agricultural and food producers. It also serves the industrial market with analytical instrumentation for sectors such as chemical, semiconductor, electronics, energy, lubricants, petrochemicals, and polymers. The Diagnostics segment is dedicated to early detection, offering instruments, reagents, assay platforms, and software for identifying genetic disorders in pregnant individuals and young children, alongside infectious disease testing. Its products facilitate the screening of genetic abnormalities, disorders, and diseases like Down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. This division also innovates technologies that support genomic workflows, leveraging protein-coupled receptor and next-generation DNA sequencing for applications in oncology, immunodiagnostics, and drug discovery. Revvity serves a diverse clientele, including pharmaceutical and biotechnology firms, laboratories, academic and research institutions, public health authorities, private healthcare organizations, medical professionals, and government bodies.
Data from the stock’s TipRanks forecast page, read 52 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗